U.S. CDC advisers back J&J COVID-19 vaccine benefits amid neurological illness reports
- Wall Street falls as surging bond yields hammer tech shares
- Ford (F) Stock Soars on $11.4 Billion EV Partnership with Battery Maker SK Innovation (SKOVF)
- Brent tops $80 a barrel on tighter supplies
- Piper Sandler Raises Estimates on Tesla (TSLA) Ahead of 'Best-Ever Quarter' in Q3
- Buy-the-dip Mentality Continues to Dominate, Last Week's $5.9 Billion Stock Inflows Were Fourth Largest Since 2008 - BofA
FILE PHOTO: A general view of the U.S. Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia September 30, 2014. REUTERS/Tami Chappell
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
(Reuters) - Despite reports of a rare neurological disorder appearing in some people who have received Johnson & Johnson's COVID-19 vaccine, the benefits of its use outweigh the risks, a U.S. Centers for Disease Control and Prevention advisory panel said on Thursday.
The U.S. Food and Drug Administration last week added a warning to its fact sheet for J&J's single-shot vaccine saying that data suggests there is an increased risk of Guillain-Barré syndrome (GBS) in the six weeks after vaccination.
The CDC advisory panel evaluated the J&J vaccine's risks and benefits after these preliminary reports of GBS from people who have gotten the shot.
Given the possible association between GBS and the vaccine, CDC will update its considerations for the use of J&J's vaccine to say that patients with a history of GBS should first look at the availability of two-shot mRNA-based vaccines from Pfizer Inc/BioNTech SE and Moderna, an agency official said.
The FDA cited 100 preliminary reports of GBS in J&J vaccine recipients including 95 serious cases that required hospitalization and one reported death.
J&J on Thursday said the known benefits on its vaccine outweigh known potential risks.
Members of a work group of the CDC Advisory Committee on Immunization Practices (ACIP) expressed "strong support" for continued use of J&J vaccine, the CDC's Sarah Mbaeyi said during the panel meeting.
The CDC will also update some of its communication materials on the vaccine, including information for medical providers on talking to patients about vaccine safety and frequently asked questions, Mbaeyi added.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Will Dunham)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Outlook Therapeutics (OTLK) Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial
- Neovasc (NVCN) REDUCER-I Study Published in EuroIntervention Journal
- Pfizer (PFE), BioNTech (BNTX) Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age
Create E-mail Alert Related CategoriesFDA, Reuters
Related EntitiesAdCom, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!